Open Access

Effect of gefitinib on serum EGFR and CYFRA21‑1 in patients with advanced non‑small cell lung cancer

  • Authors:
    • Hui Ren
    • Yang Hu
    • Tao Xie
    • Caibao Jin
    • Yanping Hu
    • Bin Yang
  • View Affiliations

  • Published online on: August 16, 2019     https://doi.org/10.3892/ol.2019.10762
  • Pages: 4167-4175
  • Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Changes of epidermal growth factor receptor (EGFR) and cytokeratin fragment antigen 21‑1 (CYFRA21‑1) in patients with advanced non‑small cell lung cancer (NSCLC) before and after gefitinib treatment were observed to explore the significance of such changes. A total of 175 patients with advanced NSCLC who were admitted to Hubei Cancer Hospital from July 2012 to October 2015 were collected and divided into two groups: the control group (85 patients who received conventional chemotherapy) and the experimental group (90 patients treated with gefitinib combined with chemotherapy). The serum expression levels of EGFR and CYFRA21‑1 were detected by enzyme‑linked immunosorbent assay (ELISA). The therapeutic efficacy and 3‑year survival of the two groups were compared, and the factors affecting the survival of the patients were analyzed. The total effective rate and local effective rate of the experimental group were significantly higher than those of the control group (P<0.05). Before treatment, no significant difference was detected in the levels of EGFR and CYFRA21‑1 between the two groups (P>0.05). After treatment, the expression levels of EGFR and CYFRA21‑1 in the two groups were significantly lower than those before treatment (P<0.05). According to the 3‑year survival rate, the experimental group was divided into the survival group and the non-survival group. Single factor analysis was performed on the general data, showing that the influencing factors of the survival include the KPS score, smoking history, number of lesions, pathological stage, EGFR, and CYFRA21‑1. Gefitinib can bring significantly improved therapeutic efficacy, lower expression levels of EGFR and CYFRA21‑1, and longer survival time for patients with advanced NSCLC. Indicators including confirmed smoking history, a KPS score less than or equal to 60 points, multiple lesions, pathological stage IV, high expression of EGFR and CYFRA21‑1, are important factors affecting the survival of patient with advanced NSCLC.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ren, H., Hu, Y., Xie, T., Jin, C., Hu, Y., & Yang, B. (2019). Effect of gefitinib on serum EGFR and CYFRA21‑1 in patients with advanced non‑small cell lung cancer. Oncology Letters, 18, 4167-4175. https://doi.org/10.3892/ol.2019.10762
MLA
Ren, H., Hu, Y., Xie, T., Jin, C., Hu, Y., Yang, B."Effect of gefitinib on serum EGFR and CYFRA21‑1 in patients with advanced non‑small cell lung cancer". Oncology Letters 18.4 (2019): 4167-4175.
Chicago
Ren, H., Hu, Y., Xie, T., Jin, C., Hu, Y., Yang, B."Effect of gefitinib on serum EGFR and CYFRA21‑1 in patients with advanced non‑small cell lung cancer". Oncology Letters 18, no. 4 (2019): 4167-4175. https://doi.org/10.3892/ol.2019.10762